SLC5A2 and Hepatic steatosis: Previous reports have suggested an improvement in hepatic fibrosis, both histologically [25] and by available surrogate markers analysis [22], although the exact pathophysiologic mechanism by which SGLT2 inhibitors improve hepatic steatosis and fibrosis has not been fully clarified.